Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracircuit potassium supplementation plus sodium zirconium cyclosilicate during hemodialysis initiation
jRCT1011260047Recruiting
- Start
- Sep 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of sodium zirconium cyclosilicate and potassium chloride in chronic kidney disease (CKD) (2 arms). Primary endpoint: Frequency of premature atrial contractions. Started Sep 2026; status: recruiting.
02
Drugs
sodium zirconium cyclosilicatepotassium chloride
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT1011260047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1011260047.